Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Minority Interest: 2009-2025

Historic Minority Interest for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to -$319,150.

  • Cumberland Pharmaceuticals' Minority Interest fell 3.05% to -$319,150 in Q3 2025 from the same period last year, while for Sep 2025 it was -$319,150, marking a year-over-year decrease of 3.05%. This contributed to the annual value of -$307,517 for FY2024, which is 10.49% up from last year.
  • According to the latest figures from Q3 2025, Cumberland Pharmaceuticals' Minority Interest is -$319,150, which was down 2.66% from -$310,868 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Minority Interest ranged from a high of -$139,283 in Q1 2021 and a low of -$343,572 during Q4 2023.
  • For the 3-year period, Cumberland Pharmaceuticals' Minority Interest averaged around -$317,625, with its median value being -$316,401 (2025).
  • Its Minority Interest has fluctuated over the past 5 years, first crashed by 195.44% in 2021, then rose by 10.49% in 2024.
  • Cumberland Pharmaceuticals' Minority Interest (Quarterly) stood at -$212,328 in 2021, then slumped by 37.58% to -$292,126 in 2022, then declined by 17.61% to -$343,572 in 2023, then increased by 10.49% to -$307,517 in 2024, then fell by 3.05% to -$319,150 in 2025.
  • Its Minority Interest stands at -$319,150 for Q3 2025, versus -$310,868 for Q2 2025 and -$316,401 for Q1 2025.